Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States
This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutation who received treatment with capmatinib, immunotherapy (IO), or chemotherapy (CT) in real-world practice settings. Data abstraction was performed by the participating physician.
Checked against the public recordLast updated Dec 7, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Novartis Pharmaceuticals
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patient was aged ≥ 18 years at the time of NSCLC diagnosis. * Had histologically confirmed advanced (stage IIIB, IIIC, or IV) NSCLC with MET exon 14 skipping mutation. * Initiated first-line (1L) treatment for aNSCLC between 1 January 2017 and date of data abstraction with one of the following treatment regimen: * Capmatinib * IO agent in monotherapy (e.g., atezolizumab, pembrolizumab) * CT regimen, single agent or combinations of CT agents (e.g., platinum agents, taxane agents, gemcitabine, pemetrexed) * Combination regimen containing IO and CT agents * Had ≥ 6 months of potential follow-up time after the initiation of 1L treatment for aNSCLC, except if the patient died sooner. * Living or deceased at the time of chart abstraction. Exclusion Criteria: * Presence of other mutations (e.g., EGFR, ALK, ROS1, RET, NTRK, BRAF, or KRAS) at any time. * Treatment with other MET inhibitors such as crizotinib or tepotinib at any time during the study period. * Participation in clinical trials related to treatment for NSCLC at any timepoint.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- NovartisEast Hanover, New Jersey
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 7, 2023. Always confirm current availability with the study team.